• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Humana Inc.

    3/5/26 5:22:13 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    FWP 1 humana-fwpmarch2026.htm FWP Document
    Filed Pursuant to Rule 433
    Registration Statement No. 333-277734
    PRICING TERM SHEET
    DATED MARCH 5, 2026
    Humana Inc.
    $1,000,000,000
    6.625% Fixed-to-Fixed Rate Junior Subordinated Notes due 2056
    The information in this pricing term sheet supplements Humana Inc.’s preliminary prospectus supplement, dated March 5, 2026 (the “Preliminary Prospectus Supplement”), and supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement. In all other respects, this pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement, including all other documents incorporated by reference therein. References to “we,” “our” and “us” refer to Humana Inc. and not to any of its subsidiaries. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus Supplement. All references to dollar amounts are references to U.S. dollars.
    Issuer:
    Humana Inc.
    Ticker:
    HUM
    Securities:
    6.625% Fixed-to-Fixed Rate Junior Subordinated Notes due 2056 (the “notes”)
    Security Type:
    SEC Registered
    Aggregate Principal Amount:$1,000,000,000
    Denominations:
    $2,000 and integral multiples of $1,000 in excess thereof
    Subordination; Ranking:
    The notes will be subordinate and junior in right of payment, to the extent and in the manner set forth in the indenture governing the junior subordinated notes, to all senior indebtedness of Humana, as described in the Preliminary Prospectus Supplement. The junior subordinated notes will be effectively junior to any of our future secured indebtedness to the extent of the assets securing that indebtedness, and will be structurally subordinated to any indebtedness and other liabilities of our subsidiaries. The junior subordinated notes will rank equally in right of payment with any future unsecured indebtedness that we may incur from time to time if the terms of such indebtedness provide that it ranks equally with the junior subordinated notes in right of payment.
    Maturity:
    September 15, 2056
    First Reset Date:
    September 15, 2031 (the “First Reset Date”)
    Optional Redemption:
    We may redeem the notes in whole or in part, on one or more occasions at a price equal to 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (i) on any day during the period commencing on the date that is 90 days prior to the First Reset Date and ending on and including the First Reset Date and (ii) after the First Reset Date, on any interest payment date for the notes.



    Right to Redeem Upon a Tax Event:
    We may, at our option, redeem the notes, in whole, but not in part, at a redemption price equal to 100% of the principal amount of the notes, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following the occurrence of a Tax Event (as defined in the Preliminary Prospectus Supplement) with respect to the notes.
    Right to Redeem Upon a Rating Agency Event:
    We may, at our option, redeem the notes, in whole, but not in part, at a redemption price equal to 102% of the principal amount of the notes, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following a Rating Agency Event (as defined in the Preliminary Prospectus Supplement) with respect to the notes.
    Interest:
    The notes will bear interest (i) from, and including, the original issuance date to, but excluding, the First Reset Date at a rate of 6.625% per year and (ii) from, and including, the First Reset Date, during each Reset Period (as defined in the Preliminary Prospectus Supplement), at a rate per year equal to the Five-year U.S. Treasury Rate (as defined in the Preliminary Prospectus Supplement) as of the most recent Reset Interest Determination Date (as defined in the Preliminary Prospectus Supplement), plus a spread of 2.891%, to be reset on each Reset Date; provided that the interest rate during any Reset Period will not reset below 6.625% (which equals the initial interest rate on the notes).
    Interest Payment Dates:
    Subject to our right to defer the payment of interest on the notes as described below, we will pay interest on the notes semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2026. Interest on the notes will accrue from March 9, 2026.
    Option to Defer Interest Payments:
    So long as no event of default with respect to the notes has occurred and is continuing, we may, on one or more occasions, defer payment of all or part of the current and accrued interest otherwise due on the notes for a period of up to 10 consecutive years (commencing on the date that the first such interest payment would otherwise have been made on the notes).
    Any deferred interest on the notes will accrue additional interest at a rate equal to the interest rate then applicable to the notes, compounded on each interest payment date, to the extent permitted by applicable law. Once we pay all deferred interest payments on the notes, including any additional interest accrued on the deferred interest (including compound interest), we can again defer interest payments on the notes as described above, but not beyond the maturity date of the notes.
    Issue Price:
    100.000% of principal amount
    Joint Book-Running Managers:
    Goldman Sachs & Co. LLC
    J.P. Morgan Securities LLC
    Mizuho Securities USA LLC
    Truist Securities, Inc.
    Wells Fargo Securities, LLC
    2


    Joint Bookrunners:
    Barclays Capital Inc.
    BofA Securities, LLC
    Citigroup Global Markets Inc.
    Morgan Stanley & Co. LLC
    PNC Capital Markets LLC
    U.S. Bancorp Investments, Inc.
    Co-Managers:BBVA Securities, Inc.
    Deutsche Bank Securities Inc.
    Academy Securities, Inc.
    BNY Mellon Capital Markets, LLC
    Fifth Third Securities, Inc.
    RBC Capital Markets, LLC
    Regions Securities LLC
    Scotia Capital (USA) Inc.
    SMBC Nikko Securities America, Inc.
    TD Securities (USA) LLC
    CastleOak Securities, L.P.
    R. Seelaus & Co., LLC
    Trade Date:
    March 5, 2026
    Expected Settlement Date:
    March 9, 2026 (T+2)
    Expected Ratings*
    (Moody’s/S&P/Fitch):
    Baa3 (Moody’s)/ BB+ (S&P)/ BB (Fitch)
    CUSIP Number / ISIN:
    444859 CE0 / US444859CE04
    Use of Proceeds:
    We intend to use the net proceeds from this offering for general corporate purposes, which may include the repayment of existing indebtedness, including borrowings under our commercial paper program. See “Use of Proceeds” in the Preliminary Prospectus Supplement.
      
    __________________
    3


    *Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
    It is expected that delivery of the notes will be made against payment therefor on March 9, 2026, which is the second business day following the trade date for the notes (such settlement cycle being referred to as “T+2”). Under Rule 15c6-1 under the U.S. Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes prior to the business day preceding the settlement date will be required, by virtue of the fact that the notes initially will settle T+2, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to the business day preceding the settlement date should consult their own advisors.
    The Issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the Issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov.
    Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the preliminary prospectus supplement if you request it from (i) Goldman Sachs & Co. LLC by calling toll-free at 1-866-471-2526, (ii) J.P. Morgan Securities LLC by email at [email protected] and [email protected], (iii) Mizuho Securities USA LLC by calling toll-free at 1-866-271-7403, (iv) Truist Securities, Inc. by calling toll-free at 1-800-685-4786 and (v) Wells Fargo Securities, LLC by calling toll-free at 1-800-645-3751.
    4
    Get the next $HUM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    12/5/2025$313.00Hold → Buy
    Jefferies
    10/14/2025$235.00Sell
    Goldman
    9/22/2025$295.00In-line
    Evercore ISI
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humana Prices $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering

    Humana Inc. (the "company") (NYSE:HUM) announced today that it has priced a public offering of $1.0 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, at 100.000 percent of the principal amount (the "Junior Subordinated Notes Offering"). The Junior Subordinated Notes Offering is expected to close on March 9, 2026, subject to the satisfaction of customary closing conditions. The company expects net proceeds from the Junior Subordinated Notes Offering will be approximately $986 million after deducting underwriters' discounts and estimated offering expenses. The company intends to use the net proceeds from the Junior Subordinated Notes Offering f

    3/5/26 7:08:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana partners with Disabled American Veterans for the sixth year

    ERLANGER, Ky., March 04, 2026 (GLOBE NEWSWIRE) -- DAV (Disabled American Veterans) has announced its continued partnership with Humana, one of the nation's leading health and well-being companies. The relationship builds on Humana's long-standing commitment to supporting veterans and expands its investment in organizations that provide critical programs and services for veterans and their families. Humana works to help people achieve their best health by partnering with communities, veterans service organizations, providers and clinicians to address challenges such as hunger, homelessness, financial strain, transportation barriers and loneliness—all factors that can impact veteran wel

    3/4/26 12:55:41 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members

    Humana Inc. (NYSE:HUM), a leading U.S. healthcare company, today announced new partnerships to improve heart health for eligible Medicare Advantage members through value-based care. Building on Humana's existing cardiac care partnership with CVAUSA's Novocardia Care Solutions division, new agreements with Karoo Health, US Heart and Vascular and Chamber Cardio further expand the company's comprehensive cardiac care program. What This Means for Medicare Advantage Members Eligible Humana Individual and Group Medicare Advantage members will have access, through their participating cardiologists, to enhanced cardiac care services designed to improve quality of life and reduce hospitalization

    3/3/26 11:45:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Ventura Joseph C converted options into 1,035 units of Humana Common and covered exercise/tax liability with 478 units of Humana Common, increasing direct ownership by 3% to 17,087 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 5:09:07 PM ET
    $HUM
    Medical Specialities
    Health Care

    President, Insurance Renaudin George Ii covered exercise/tax liability with 419 units of Humana Common and converted options into 1,035 units of Humana Common, increasing direct ownership by 4% to 16,075 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 3:43:58 PM ET
    $HUM
    Medical Specialities
    Health Care

    SVP, Chief Accting Off & Cont. Felter John-Paul W. was granted 5,669 units of Humana Common, converted options into 165 units of Humana Common and covered exercise/tax liability with 84 units of Humana Common, increasing direct ownership by 332% to 7,484 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 4:04:34 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    SEC Filings

    View All

    SEC Form FWP filed by Humana Inc.

    FWP - HUMANA INC (0000049071) (Subject)

    3/5/26 5:22:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Humana Inc.

    424B5 - HUMANA INC (0000049071) (Filer)

    3/5/26 8:38:11 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form POSASR filed by Humana Inc.

    POSASR - HUMANA INC (0000049071) (Filer)

    3/5/26 8:29:12 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/21/24 10:37:23 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Humana from Overweight to Equal Weight and set a new price target of $290.00

    1/7/26 8:56:48 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/16/24 4:29:43 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/14/24 10:02:59 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/13/24 5:06:27 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    National Mall of Pickleball Returns for Third Year with Expanded Footprint and New, Central Location

    The National Mall of Pickleball will celebrate America's most accessible sport and the game that serves all in the heart of the National Mall this September The Trust for the National Mall, Humana (NYSE:HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America's Front Yard, the National Mall, for a third year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625316935/en/ From Friday, September 19 through Sunday, September 21, 2025, the general public can experience a weekend full of pickleball programming, activities, and community with captivating views o

    6/25/25 9:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Launches "Invite" Campaign to Inspire Active Aging Through Pickleball and Community Connection

    Humana Inc. (NYSE:HUM), a leading health and well-being company, is expanding its commitment to senior wellness with the launch of Invite, a new campaign designed to encourage older adults of all fitness levels to stay active, connected and engaged – starting with the fastest-growing sport in America: pickleball. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618737488/en/As part of Humana's new "Invite" campaign, the health and wellness company debuted a television spot featuring senior pickleball athletes extending an open invitation to others to join the fun, stay social, and support their physical and mental well-being. A

    6/18/25 8:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Financials

    Live finance-specific insights

    View All

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Inc. to Release Fourth Quarter 2025 Results on February 11, 2026

    Humana Inc. (NYSE:HUM) will release its financial results for the fourth quarter 2025 (4Q25), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on February 11, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026. A webcast of the 4Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/. If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIb3f01f81dd3b4f7cb8331d38dad89

    1/9/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care